{
    "clinical_study": {
        "@rank": "137798", 
        "arm_group": [
            {
                "arm_group_label": "Treatment 1", 
                "arm_group_type": "Experimental"
            }, 
            {
                "arm_group_label": "Treatment 2", 
                "arm_group_type": "Experimental"
            }, 
            {
                "arm_group_label": "Treatment 3", 
                "arm_group_type": "Experimental"
            }, 
            {
                "arm_group_label": "Placebo", 
                "arm_group_type": "Placebo Comparator"
            }
        ], 
        "brief_summary": {
            "textblock": "This clinical trial is designed to evaluate the efficacy, dose-response and safety of\n      WIN-901X in Asthma patients."
        }, 
        "brief_title": "Safety and Efficacy of WIN-901X in Asthma", 
        "completion_date": {
            "#text": "November 2013", 
            "@type": "Actual"
        }, 
        "condition": "Asthma", 
        "condition_browse": {
            "mesh_term": "Asthma"
        }, 
        "detailed_description": {
            "textblock": "Double blinded, Randomized, Placebo Controlled, Multi-center, Phase 2 : Exploratory Clinical\n      Study to Evaluate the Efficacy, Dose-response and Safety of WIN-901X in Asthma Patients"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Greater than or equal to 20 and less than 80 years of age\n\n          -  Have physician diagnosed asthma with irreversible airway obstruction at least 6\n             months prior to the screening\n\n          -  FEV1 between 60% and 85% before inhaling fast-acting bronchodilator at screening\n\n          -  No history of smoking at least one year prior to the screening\n\n          -  Having voluntarily signed an informed consent\n\n        Exclusion Criteria:\n\n          -  Have visited emergency room due to the worsening asthma symptoms, within 4 weeks\n             before the screening\n\n          -  Have been hospitalized due to an acute worsening of asthma within 3 months before the\n             screening\n\n          -  Have a history of laryngitis, pyrexia, sinusitis, otitis media, respiratory tract\n             infection, and infectious rhinitis within 4 weeks prior to the screening\n\n          -  Have malignant tumor"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "79 Years", 
            "minimum_age": "20 Years"
        }, 
        "enrollment": {
            "#text": "209", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "March 25, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01820481", 
            "org_study_id": "WIN-901X-P2"
        }, 
        "intervention": [
            {
                "arm_group_label": "Treatment 1", 
                "description": "100mg Bid, PO, 12weeks", 
                "intervention_name": "WIN-901X dose level 1", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Treatment 2", 
                "description": "200mg Bid, PO, 12weeks", 
                "intervention_name": "WIN-901X dose level 2", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Treatment 3", 
                "description": "300mg Bid, PO, 12weeks", 
                "intervention_name": "WIN-901X dose level 3", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Placebo", 
                "description": "Bid, PO, 12weeks", 
                "intervention_name": "Placebo", 
                "intervention_type": "Drug"
            }
        ], 
        "is_fda_regulated": "No", 
        "keyword": [
            "Asthma", 
            "Bronchial Diseases", 
            "Respiratory Tract Diseases", 
            "Lung Diseases, Obstructive", 
            "Lung Diseases"
        ], 
        "lastchanged_date": "December 5, 2013", 
        "location": {
            "facility": {
                "address": {
                    "city": "Suwon", 
                    "country": "Korea, Republic of"
                }, 
                "name": "Ajou University Medical Center"
            }
        }, 
        "location_countries": {
            "country": "Korea, Republic of"
        }, 
        "number_of_arms": "4", 
        "official_title": "Double Blinded, Randomized, Placebo Controlled, Multi-center, Phase 2 : Exploratory Clinical Study to Evaluate the Efficacy, Dose-response and Safety of WIN-901X in Asthma Patients", 
        "overall_official": {
            "affiliation": "Yes", 
            "last_name": "Park Hae Sim, M.D., Professor", 
            "role": "Study Chair"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "Korea: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "November 2013", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "description": "FEV1: Forced Expiratory Volume In One Second", 
            "measure": "Compare the change of FEV1% to the baseline after the medication", 
            "safety_issue": "No", 
            "time_frame": "Baseline, week 12"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01820481"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "ACQ: Asthma Control Questionnaire", 
                "measure": "Compare the change of ACQ to the baseline after the medication", 
                "safety_issue": "No", 
                "time_frame": "Baseline, week 12"
            }, 
            {
                "measure": "Ratio of the date, where no rescue drug was used, during the trial", 
                "safety_issue": "No", 
                "time_frame": "Baseline, week 12"
            }, 
            {
                "measure": "Ratio of symptom free days during the trial", 
                "safety_issue": "No", 
                "time_frame": "Baseline, week 12"
            }
        ], 
        "source": "Whanin Pharmaceutical Company", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Whanin Pharmaceutical Company", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "September 2012", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "December 2013"
    }
}